View Older Stories

Sep 17, 2026 07:44AM Clearmind Medicine testifies at FDA psychedelic hearing in D.C.

Sep 11, 2026 08:01AM Clearmind enrolls first AUD patients in CMND-100 trial

Sep 8, 2026 07:43AM Yale approves Clearmind Medicine patient recruitment for CMND-100 trial

Sep 1, 2026 07:37AM Clearmind starts Phase IIa trial of CMND-100 for alcohol disorder

Aug 24, 2026 08:51AM SciSparc unit files U.S. patent for MDMA-PEA combination for PTSD

Aug 24, 2026 08:05AM Clearmind files U.S. patent for MDMA-PEA combination to treat PTSD

Aug 13, 2026 07:36AM Clearmind gets DSMB approval to test CMND-100 in AUD patients

Aug 6, 2026 08:00AM Clearmind gets clearance to advance AUD drug trial to patient cohorts

Jul 30, 2026 08:30AM Clearmind reports no serious adverse events in CMND-100 dose trial

Jul 28, 2026 07:47AM Clearmind completes Part A of Phase I/II trial for alcohol disorder drug

Jul 20, 2026 07:55AM Clearmind Medicine files Hong Kong patent for PTSD compounds

Jul 17, 2026 07:32AM FDA issues psychedelic therapy guidance as Clearmind notes federal push

Jul 16, 2026 09:30AM Clearmind reports improved nasal retention for its MEAI drug formulation

Jul 13, 2026 08:17AM Clearmind reports early safety data from CMND-100 alcohol disorder trial

Jul 10, 2026 08:32AM Clearmind Medicine submits response to HHS addiction treatment RFI

Jul 7, 2026 07:43AM Clearmind reports MEAI intranasal formulation feasibility study success

Jun 22, 2026 08:07AM Clearmind completes Part A of FDA-regulated AUD drug trial

Jun 16, 2026 07:32AM Clearmind Medicine completes Part A dosing in Phase I/II alcohol disorder trial

May 29, 2026 08:41AM Clearmind Medicine files Japanese patent for depression treatment compound

May 26, 2026 08:25AM Clearmind Medicine receives Johns Hopkins approval for CMND-100 trial parts

May 12, 2026 08:41AM Clearmind Medicine doses 20th participant in alcohol disorder trial

May 5, 2026 08:53AM Clearmind Medicine files European patent application for PTSD compounds

Apr 20, 2026 04:03PM Clearmind Medicine responds to Trump executive order on psychedelic drugs

Apr 20, 2026 07:15AM Clearmind Medicine meets safety endpoint in alcohol disorder trial

Apr 14, 2026 07:32AM Clearmind Medicine's CMND-100 meets primary endpoint in phase trial

Mar 30, 2026 08:32AM Clearmind Medicine completes treatment for 18 participants in phase 1 trial

Mar 17, 2026 09:15AM Clearmind Medicine secures six Hong Kong patents for psychedelic combinations

Mar 13, 2026 07:46AM Clearmind Medicine files Hong Kong patent for depression therapy combo

Mar 11, 2026 09:08AM Clearmind Medicine advances CMND-100 trial enrollment following positive results

Mar 10, 2026 08:59AM Clearmind Medicine receives international patent for weight loss therapy

Mar 4, 2026 07:30AM Clearmind Medicine advances to next phase of alcohol disorder trial

Feb 19, 2026 04:15PM LDB Capital Corp. Announces Definitive Agreement for Proposed Qualifying Transaction with Eventer Technologies Ltd.

Feb 9, 2026 08:17AM Clearmind Medicine reports positive safety data for alcohol disorder drug

Feb 9, 2026 08:17AM Clearmind Medicine reports positive safety data from CMND-100 trial

Feb 9, 2026 08:00AM Taurus Gold Corp. Management Updates

Feb 6, 2026 08:02AM Clearmind Medicine partners with Polyrizon for intranasal MEAI formulation

Feb 6, 2026 07:57AM Polyrizon partners with Clearmind to develop intranasal MEAI formulation

Jan 14, 2026 08:55AM Clearmind Medicine completes treatment for second patient cohort in trial

Dec 24, 2025 09:15AM Clearmind Medicine advances alcohol disorder drug trial, reports safety data

Dec 16, 2025 08:45AM Clearmind Medicine completes second cohort enrollment in AUD trial

Dec 5, 2025 05:01PM Clearmind Medicine receives NASDAQ minimum bid price deficiency notice

Dec 2, 2025 07:57AM Clearmind Medicine doses first patient with CMND-100 at Hadassah Medical Center

Dec 1, 2025 08:57AM Clearmind Medicine receives safety board approval for alcohol disorder trial

Nov 26, 2025 04:18PM Clearmind Medicine (CMND) files for 5.78M share offering by selling stockholders

Nov 25, 2025 07:17AM Clearmind Medicine enrolls first patient at Tel Aviv medical center

Nov 24, 2025 08:51AM Clearmind Medicine receives approval to continue phase I trial

Nov 20, 2025 06:45AM SciSparc files Israeli patent for depression treatment combination therapy

Nov 20, 2025 06:01AM Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site

Nov 18, 2025 08:57AM Clearmind Medicine reports positive phase I/IIa trial results for AUD treatment

Nov 17, 2025 07:55AM Clearmind Medicine files Israeli patent for depression treatment

View Older Stories